tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Christopher Neyor, 1 are a HOLD (12.5%), 6 are a BUY (75%), 1 are a SELL (12.5%).
Analyst Christopher Neyor, carries an average stock price target met ratio of 41.67% that have a potential upside of 9.74% achieved within 82 days. Previously, Christopher Neyor worked at JPMORGAN, CREDIT SUISSE.
Christopher Neyor’s has documented 15 price targets and ratings displayed on 3 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on ITOS, Iteos Therapeutics at 13-May-2025.
Analyst best performing recommendations are on PCRX (PACIRA PHARMACEUTICALS).
The best stock recommendation documented was for ITOS (ITEOS THERAPEUTICS) at 5/13/2025. The price target of $8 was fulfilled within 6 days with a profit of $0.15 (1.91%) receiving and performance score of 3.18.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 21-Mar-2017
$36.5
$0.11 (0.30%)
$38
22 days ago
(09-Oct-2026)
5/9 (55.56%)
$0.19 (0.52%)
743
Buy Since 30-Apr-2020
$33
23 days ago
(08-Oct-2026)
18/33 (54.55%)
$8.13 (32.69%)
314
Buy Since 08-Oct-2026
$36
$-0.39 (-1.07%)
$25
23 days ago
(08-Oct-2026)
4/6 (66.67%)
$-0.39 (-1.07%)
656
Sell Since 19-Feb-2025
$36.5
$0.11 (0.30%)
$24
23 days ago
(08-Oct-2026)
2/4 (50%)
$0.11 (0.30%)
185
Buy Since 07-Nov-2025
$31
$-5.39 (-14.81%)
$32
24 days ago
(07-Oct-2026)
7/10 (70%)
$5.8 (23.02%)
311
